Craig Labbate, MD

Craig Labbate, MD, is a board-certified urologist at Kelsey-Seybold Clinic. He earned his Doctor of Medicine degree in 2015 at Baylor College of Medicine in Houston, Texas. Dr. Labbate then went to the University of Chicago Hospital to complete a General Surgery internship in 2016. He remained at the University of Chicago Hospital to complete his Urology residency in 2021. Relocating back to Houston, Dr. Labbate then completed a fellowship in Urologic Oncology in 2023 at UT MD Anderson Cancer Center. He joined Kelsey-Seybold in August 2025.

As a urologist, Dr. Labbate strives to help at least one person every day, as did his father, who was a physician. Dr. Labbate treats a broad range of urologic conditions and specializes in surgical interventions for urologic cancers, including robotic surgery procedures. Some of the conditions he treats include enlarged prostate, kidney stones, urologic cancers, blood in the urine, and more. For Dr. Labbate, one of the best parts of practicing medicine is completing surgery and knowing his actions helped heal someone that day.

Philosophy of Care

With a patient-centric approach, Dr. Labbate takes time to listen and focus on his patients’ concerns – then engages them to participate in making decisions about their health. He also personalizes care to strike a balance between achieving his patients’ goals and minimizing the side effects of therapy.

Hobbies & Interests

Dr. Labbate’s two beautiful children and rascal golden retriever are his entire world – and he dedicates himself wholly to taking care of them.

Awards & Publications

Awards

• Third Place Chicago Urological Society Huggins Resident Essay Contest, 2019
• Third Place Annual Schoenberg Research Contest, 2019
• AUA North Central Section Resident Bowl Champion, 2019
• Alpha Omega Alpha
• Phi Beta Kappa

Publications

Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour SB, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, Lotan Y, Dickstein RJ. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. Urol Oncol. 2024 Jan;42(1):20.e17-20.e23.

Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. Journal of Urology. 2024 Feb;211(2):241-255. doi: 10.1097/JU.0000000000003778.

Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 Jan;209(1):49-57. doi: 10.1097/JU.0000000000002972

Rose KM, Murray KS, Labbate CV, Woldu S, Linehan J, Jacob J, Kaimakliotis H, Dickstein R, Feldman A, Matin SF, Lotan Y, Humphreys MR, Sexton WJ. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. Eur Urol Focus. 2023 Sep;9(5):807-812. doi: 10.1016/ j.euf.2023.03.016.

Labbate CV, Woldu S, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner B, Feldman A, Lotan Y, Matin SF. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma, J Urol. 2023 May;209(5):872-881. doi: 10.1097/ JU.0000000000003185.e

Woldu SL, Labbate CV, Murray KS, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. Urol Oncol. 2023 Mar;41(3):147.e15-147.e21. doi: 10.1016/j.urolonc.2022.10.029.

Labbate CV, Hensley PJ, Miest TM, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke A, Gao JJ, Guo CG, Czerniak, BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. “Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma” Urol Onc. 2022 Oct;40(10)

Labbate CV, Kuchta K, Park, ST, Agarwal PK, Smith ND. “Incidence of Preoperative Antibiotic Use and Its Association with Postoperative Infectious Complications after Radical Cystectomy”. Urology. 2022 Jun;164:169-177.

Packiam VT, Labbate CV, Boorjian SA, Tarrell R, Cheville JC, Avulova S, Sharma V, Tsivian M, Adamic B, Mahmoud M, Werntz RP, Smith ND, Karnes RJ, Tollefson MK, Steinberg GD, Frank I. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high grade non-muscle invasive bladder cancer: A multi-institution analysis. Urol Oncol. 2021 Jan 20:S1078-1439(21)00003-X.

Adamic, B, Kirkire, L, Andolfi, C, Labbate, C, Aizen, J, Gundeti, M. Robot-assisted laparoscopic augmentation ileocystoplasty and Mitrofanoff appendicovesicostomy in children: Step-by-step and modifications to UChicago technique. BJUI Compass. 2020; 1: 32– 40. https://doi.org/10.1002/bco2.7

Na R, Labbate CV Yu Hongjie, Shi Zhuqing, Fantus RJ, Wang CH, Andriole GL, Isaacs WB, Zheng SL, Helfand BT, Xu J. “Genetic Risk Score Is Associated With Age of Prostate Cancer Diagnosis: Results from the REDUCE trial” JAMA Netw Open. 2019;2(12):e1916439 Xu J,

Labbate CV, Isaacs WB, Helfand BT. “Inherited Risk Assessment of Prostate Cancer: It Takes Three To Do It Right” Prostate Cancer and Prostatic (2019) https:// doi.org/10.1038/s41391-019-0165-y

Labbate C, Werntz RP, Adamic B, Steinberg GD “The Impact of Omission of Intraoperative Frozen Section Prior to Orthotopic Neobladder Reconstruction.” Journal of Urology 2019;202(4):763–769.

Labbate C, Hagotai K, Werntz RP, Stadler WM, Steinberg GD, Eggener S, Sweis RF. “Complete Response of Renal Cell Carcinoma Vena Cava Tumor Thrombus to Neoadjuvant Immunotherapy” Journal of Immunotherapy for Cancer. 2019;7(1):66.

Riedinger CB, Labbate C, Werntz RP, Eggener SE. “Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later.” Urology 2018:Dec 122: 16-18

Kovac JR, Labbate C, Ramasamy R, Tang D, Lipshultz L “Effects of cigarette smoking on Erectile Dysfunction” Andrologia 2015. 47 1087-1092